Pages that link to "Q42742064"
Jump to navigation
Jump to search
The following pages link to Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia (Q42742064):
Displaying 50 items.
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia (Q24313505) (← links)
- Protein kinases and phosphatases in the control of cell fate (Q24604987) (← links)
- Targeting mTOR for the treatment of AML. New agents and new directions (Q24617223) (← links)
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance (Q24645668) (← links)
- The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance (Q26739246) (← links)
- Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence (Q26770388) (← links)
- How I treat pediatric acute myeloid leukemia (Q26992280) (← links)
- Childhood acute myeloid leukaemia (Q27005960) (← links)
- Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia (Q28271726) (← links)
- Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia (Q33493174) (← links)
- MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras (Q33622710) (← links)
- Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. (Q33732534) (← links)
- Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. (Q33745075) (← links)
- What are the endpoints of therapy for acute leukemias? Old definitions and new challenges (Q33775647) (← links)
- Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia (Q33843736) (← links)
- Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells (Q33875609) (← links)
- Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells (Q33998634) (← links)
- The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. (Q34024558) (← links)
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias (Q34063343) (← links)
- Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside (Q34097586) (← links)
- XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. (Q34100957) (← links)
- Inhibiting CCN1 blocks AML cell growth by disrupting the MEK/ERK pathway (Q34127147) (← links)
- Functional proteomic profiling of AML predicts response and survival (Q34184598) (← links)
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies (Q34367804) (← links)
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias (Q34451540) (← links)
- Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia (Q34926036) (← links)
- Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia (Q35031403) (← links)
- Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells (Q35040064) (← links)
- Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors (Q35114769) (← links)
- Multiple model-informed open-loop control of uncertain intracellular signaling dynamics (Q35145197) (← links)
- Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia (Q35172210) (← links)
- Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients (Q35316765) (← links)
- Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. (Q35525811) (← links)
- Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions (Q35750567) (← links)
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (Q35752048) (← links)
- Dampened ERK signaling in hematopoietic progenitor cells in rheumatoid arthritis (Q35830840) (← links)
- Dynamic Modeling and Analysis of the Cross-Talk between Insulin/AKT and MAPK/ERK Signaling Pathways (Q35940709) (← links)
- Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia (Q36028489) (← links)
- Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy (Q36065836) (← links)
- Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia (Q36065874) (← links)
- A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia (Q36078593) (← links)
- Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients (Q36324321) (← links)
- Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway (Q36384328) (← links)
- A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species (Q36426254) (← links)
- The VEGF pathway in cancer and disease: responses, resistance, and the path forward. (Q36526512) (← links)
- High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia (Q36591388) (← links)
- Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies (Q36812355) (← links)
- Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy (Q36973814) (← links)
- Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase (Q37031282) (← links)
- Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis (Q37043876) (← links)